Research Topics
Species | Jayanthi S LeaSummaryAffiliation: University of Texas Southwestern Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cervical cancerJayanthi S Lea
University of Texas Southwestern School of Medicine, Dallas, TX 75390 9032, USA
Obstet Gynecol Clin North Am 39:233-53. 2012..Improvements in radiation techniques and molecular targeted therapy are the current research venues in cervical cancer...
Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cellsJayanthi S Lea
Division ofGynecologic Oncology, Hamon Center of Therapeutic Oncology Research, University ofTexas Southwestern Medical Center, Dallas, TX75390 9032, USA
Reprod Sci 14:20-8. 2007..RNA interference targeting the E7 portion of the bicistronic HPV 18 mRNA can silence both E6 and E7 oncoproteins and is most effective in cervical cancer growth inhibition...- Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesisJayanthi S Lea
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Am J Obstet Gynecol 190:674-9. 2004..The purpose of this study was to determine the association between active tobacco exposure and aberrant p16 promoter methylation in primary cervical squamous cell cancer and high-grade squamous cervical dysplasia... - Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinomaJayanthi S Lea
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9032, USA
Gynecol Oncol 91:558-62. 2003..The purpose of this study was to identify poor prognostic factors of low-risk stage IB1 cervical adenocarcinoma.. - Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker developmentJayanthi S Lea
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
J Soc Gynecol Investig 11:329-37. 2004..The goal of this study was to confirm the utility of homozygous deletions, aberrant methylation, and immunohistochemical evaluations of FHIT as functionally relevant determinants of FHIT expression... - Endocervical curettage at conization to predict residual cervical adenocarcinoma in situJayanthi S Lea
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9032, USA
Gynecol Oncol 87:129-32. 2002..CONCLUSION: ECC performed at the time of conization may be a useful tool for predicting residual AIS in women considering fertility preservation... - Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort studyJohn O Schorge
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75390, USA
Am J Obstet Gynecol 188:640-4. 2003..We compared the clinical outcome of cervical adenocarcinoma in Hispanic and white women to determine whether race was an independent predictor of survival... - Postconization surveillance of cervical adenocarcinoma in situ. A prospective trialJohn O Schorge
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390 9032, USA
J Reprod Med 48:751-5. 2003..To conduct a surveillance trial after conization to prospectively determine the outcome of conservative management of adenocarcinoma in situ (AIS)... - Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissectionJayanthi S Lea
Division of Gynecologic Oncology, University of Texas Southwestern, Dallas, Texas 75390, USA
Gynecol Oncol 84:285-8. 2002..CONCLUSIONS: Early-stage cervical adenocarcinoma primarily treated by surgical intent has a very low risk of para-aortic metastases. These were detected only when there was gross evidence of nodal or adnexal disease... - Adenocarcinoma of the cervixJohn O Schorge
Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390, USA
Curr Treat Options Oncol 5:119-27. 2004..Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin. Management of recurrence should be individualized, depending on the location of disease and the type of previous therapy... - P16 as a molecular biomarker of cervical adenocarcinomaJohn O Schorge
Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Tex, USA
Am J Obstet Gynecol 190:668-73. 2004..Cervical adenocarcinomas are increasing in incidence each year. The aim of this study was to identify a molecular biomarker to improve early detection... - Implications of EGFR inhibition in ovarian cancer cell proliferationShawna L Bull Phelps
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9032, USA
Gynecol Oncol 109:411-7. 2008..Targeted inhibition of EGFR via its tyrosine kinase domain is a successful treatment in lung cancer. Our objective was to correlate EGFR over-expression and growth inhibition, by EGF receptor inhibitors, in ovarian cancer... - Management of low-risk gestational trophoblastic neoplasia in indigent womenJohn O Schorge
Southwestern Trophoblastic Disease Center, Division of Gynecologic Oncology, Dep of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, 75390 9032, USA
J Reprod Med 48:780-4. 2003..To identify the most effective dosing regimen for indigent patients with low-risk gestational trophoblastic neoplasia (GTN) at high risk of noncompliance... - Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivityShawna L Bull Phelps
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 8593, USA
Am J Obstet Gynecol 200:180.e1-7. 2009..Secreted protein acidic and rich in cysteine (SPARC) influences the growth of several solid tumors. Our objectives were to determine the effect of SPARC on the growth and response to cisplatin therapy of platinum-resistant ovarian cancer... - Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancerJohn O Schorge
Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Int J Gynaecol Obstet 108:123-7. 2010..To determine the risks and benefits of secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer... - Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survivalJayanthi S Lea
University of Texas Southwestern Medical Center, Dallas, Texas 75390-9032, USA
Gynecol Oncol 84:115-9. 2002..Prospective, multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease...